SG11202002258WA - Anti-adrenomedullin (adm) binder for use in therapy or prevention of symptoms of illness - Google Patents
Anti-adrenomedullin (adm) binder for use in therapy or prevention of symptoms of illnessInfo
- Publication number
- SG11202002258WA SG11202002258WA SG11202002258WA SG11202002258WA SG11202002258WA SG 11202002258W A SG11202002258W A SG 11202002258WA SG 11202002258W A SG11202002258W A SG 11202002258WA SG 11202002258W A SG11202002258W A SG 11202002258WA SG 11202002258W A SG11202002258W A SG 11202002258WA
- Authority
- SG
- Singapore
- Prior art keywords
- adrenomedullin
- adm
- illness
- symptoms
- therapy
- Prior art date
Links
- 239000011230 binding agent Substances 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 208000024891 symptom Diseases 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17192999 | 2017-09-25 | ||
EP17203370 | 2017-11-23 | ||
PCT/EP2018/075987 WO2019057992A2 (en) | 2017-09-25 | 2018-09-25 | Anti-adrenomedullin (adm) binder for use in therapy or prevention of symptoms of illness |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202002258WA true SG11202002258WA (en) | 2020-04-29 |
Family
ID=63722372
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202002258WA SG11202002258WA (en) | 2017-09-25 | 2018-09-25 | Anti-adrenomedullin (adm) binder for use in therapy or prevention of symptoms of illness |
Country Status (12)
Country | Link |
---|---|
US (1) | US20220227854A1 (en) |
EP (4) | EP4159230A1 (en) |
JP (1) | JP7461875B2 (en) |
KR (1) | KR20200088302A (en) |
CN (1) | CN111511390A (en) |
AU (2) | AU2018335438A1 (en) |
BR (1) | BR112020005450A2 (en) |
CA (1) | CA3076691A1 (en) |
IL (1) | IL273533A (en) |
MX (1) | MX2020003538A (en) |
SG (1) | SG11202002258WA (en) |
WO (1) | WO2019057992A2 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112022002856A2 (en) | 2019-08-30 | 2022-08-09 | 4TEEN4 Pharmaceuticals GmbH | THERAPY GUIDANCE AND/OR THERAPY MONITORING FOR SHOCK TREATMENT |
EP3871689A1 (en) * | 2020-02-26 | 2021-09-01 | sphingotec GmbH | Anti-adm-antibodies binding to the free n-terminus for accelerated transition of adm-gly to bio-adm in patients with adm-gly/ bio-adm ratio above a threshold and combination with vitamin c |
JP2023515042A (en) * | 2020-02-27 | 2023-04-12 | アドレノメト アクチェンゲゼルシャフト | Anti-Adrenomedullin (ADM) Antibody or Anti-ADM Antibody Fragment or Anti-ADM Non-Ig Scaffold for Use in Treatment or Prevention of Shock |
US20210285949A1 (en) * | 2020-03-16 | 2021-09-16 | Sphingotec Gmbh | Pro-adrenomedullin or fragment thereof in patients infected with corona virus and treatments with binder against adrenomedullin |
CN111893085A (en) * | 2020-08-04 | 2020-11-06 | 北京臻溪谷医学研究中心(有限合伙) | Method for obtaining artificial skin through stem cell in-vitro differentiation and application thereof |
WO2024017331A1 (en) * | 2022-07-20 | 2024-01-25 | 上海济煜医药科技有限公司 | Anti-adrenomedulin non-neutralizing antibody, method for preparing same, and use thereof |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
SG48759A1 (en) | 1990-01-12 | 2002-07-23 | Abgenix Inc | Generation of xenogenic antibodies |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
CA2109602C (en) | 1990-07-10 | 2002-10-01 | Gregory P. Winter | Methods for producing members of specific binding pairs |
AU3328493A (en) | 1991-12-17 | 1993-07-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
MXPA04001804A (en) | 2001-08-30 | 2005-03-07 | Biorexis Pharmaceutical Corp | Modified transferrin fusion proteins. |
ATE528014T1 (en) | 2002-06-07 | 2011-10-15 | Dyax Corp | POLYPEPTIDE WITH MODIFIED KUNITZ DOMAINS |
US20050164301A1 (en) | 2003-10-24 | 2005-07-28 | Avidia Research Institute | LDL receptor class A and EGF domain monomers and multimers |
US20100028995A1 (en) | 2004-02-23 | 2010-02-04 | Anaphore, Inc. | Tetranectin Trimerizing Polypeptides |
EP1793847A2 (en) | 2004-09-21 | 2007-06-13 | NascaCell IP GmbH | Use of microproteins as tryptase inhibitors |
DK2231860T3 (en) | 2007-12-19 | 2011-12-05 | Affibody Ab | Polypeptide derived protein A and capable of binding PDGF |
CA2742241C (en) | 2008-11-03 | 2019-12-10 | Molecular Partners Ag | Binding proteins inhibiting the vegf-a receptor interaction |
CA2772162C (en) | 2009-08-27 | 2018-05-22 | Covagen Ag | Anti-il-17a fynomers and medical uses thereof |
US8748351B2 (en) | 2009-12-14 | 2014-06-10 | Scil Proteins Gmbh | Method for identifying hetero-multimeric modified ubiquitin proteins with binding capability to ligands |
ES2729652T3 (en) | 2010-06-08 | 2019-11-05 | Pieris Pharmaceuticals Gmbh | Lacrimal lipocalin mutein bound to IL-4R alpha |
WO2013072513A1 (en) | 2011-11-16 | 2013-05-23 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation |
AU2012338730B2 (en) * | 2011-11-16 | 2017-07-06 | Adrenomed Ag | Anti-adrenomedullin (ADM) antibody or anti-ADM antibody fragment or anti-ADM non-Ig scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition |
PL2780717T3 (en) * | 2011-11-16 | 2017-06-30 | Sphingotec Gmbh | Adrenomedullin assays and methods for determining mature adrenomedullin |
DK2594588T3 (en) * | 2011-11-16 | 2014-07-21 | Adrenomed Ag | Anti-Adrenomedullin (ADM) antibody or anti-ADM antibody fragment or anti-ADM non-Ig protein scaffold for use in therapy |
CN108362885B (en) * | 2013-03-20 | 2021-05-14 | 斯弗因高泰克有限公司 | Adrenomedullin for guiding blood pressure lowering therapy |
US11596699B2 (en) * | 2016-04-29 | 2023-03-07 | CureVac SE | RNA encoding an antibody |
BR112019011713A2 (en) * | 2016-12-16 | 2019-10-15 | Adrenomed Ag | anti-adrenomedulin antibody (adm) or anti-adm antibody fragment or anti-adm framework not for use in the intervention and therapy of congestion in a patient in need thereof |
-
2018
- 2018-09-25 EP EP22198142.6A patent/EP4159230A1/en active Pending
- 2018-09-25 EP EP18781997.4A patent/EP3687567A2/en active Pending
- 2018-09-25 JP JP2020517143A patent/JP7461875B2/en active Active
- 2018-09-25 KR KR1020207011620A patent/KR20200088302A/en not_active Application Discontinuation
- 2018-09-25 EP EP22198106.1A patent/EP4159229A1/en active Pending
- 2018-09-25 SG SG11202002258WA patent/SG11202002258WA/en unknown
- 2018-09-25 CA CA3076691A patent/CA3076691A1/en active Pending
- 2018-09-25 US US16/650,474 patent/US20220227854A1/en active Pending
- 2018-09-25 WO PCT/EP2018/075987 patent/WO2019057992A2/en active Application Filing
- 2018-09-25 EP EP21154857.3A patent/EP3854414A1/en not_active Withdrawn
- 2018-09-25 CN CN201880062062.1A patent/CN111511390A/en active Pending
- 2018-09-25 AU AU2018335438A patent/AU2018335438A1/en active Pending
- 2018-09-25 BR BR112020005450-0A patent/BR112020005450A2/en unknown
- 2018-09-25 MX MX2020003538A patent/MX2020003538A/en unknown
-
2020
- 2020-03-23 IL IL273533A patent/IL273533A/en unknown
-
2023
- 2023-03-09 AU AU2023201479A patent/AU2023201479A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP4159229A1 (en) | 2023-04-05 |
WO2019057992A2 (en) | 2019-03-28 |
KR20200088302A (en) | 2020-07-22 |
US20220227854A1 (en) | 2022-07-21 |
RU2020114429A (en) | 2021-10-27 |
CA3076691A1 (en) | 2019-03-28 |
JP7461875B2 (en) | 2024-04-04 |
EP3854414A1 (en) | 2021-07-28 |
EP4159230A1 (en) | 2023-04-05 |
MX2020003538A (en) | 2020-07-29 |
AU2018335438A1 (en) | 2020-04-09 |
WO2019057992A3 (en) | 2019-05-02 |
IL273533A (en) | 2020-05-31 |
JP2020535151A (en) | 2020-12-03 |
AU2023201479A1 (en) | 2023-04-13 |
BR112020005450A2 (en) | 2020-09-29 |
EP3687567A2 (en) | 2020-08-05 |
CN111511390A (en) | 2020-08-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL273533A (en) | Anti-adrenomedullin (adm) binder for use in therapy or prevention of symptoms of illness | |
HK1251257A1 (en) | Use of exosomes for the treatment of disease | |
EP2981274A4 (en) | Probiotic strains for use in treatment or prevention of osteoporosis | |
HK1225637A1 (en) | Prophylactic and/or therapeutic agent for functional gastrointestinal disorders | |
FI3197556T3 (en) | Composition for the prevention and/or treatment of allergy symptoms | |
GB201522329D0 (en) | Use of adjuvants for the prevention and/or treatment of autoimmune diseases | |
PL3120852T3 (en) | Preventive and/or therapeutic agent for immune diseases | |
IL252493B (en) | Compounds for use in the prevention or treatment of cancer | |
HUE064192T2 (en) | Use of delgocitinib for the treatment of chronic hand eczema | |
GB201700526D0 (en) | Therapeutic use | |
PT3191112T (en) | Dipeptidyl ketoamide compounds and their use for the treatment and/or prevention of fat accumulation | |
EP3720449C0 (en) | Composition for use in the prevention or treatment of salmonellosis | |
IL259383A (en) | Compound for use in the prevention and treatment of neurodegenerative diseases | |
RS65009B1 (en) | Composition for use in the treatment of intestinal alterations | |
IL247616B (en) | Centrally acting acetylcholinesterase inhibitors for the prevention and/or treatment of chemically induced neuropathies and the symptoms thereof, and corresponding compositions, uses, methods and kit | |
SG10201607658RA (en) | Electronic gaming system adapted for simultaneous use of multiple users | |
EP3222281A4 (en) | Preventive and therapeutic agent for celiac disease | |
HK1257288A1 (en) | Use of inhibitors of the activity or function of pi3k for the treatment of primary sjögren's syndrome | |
EP3297443A4 (en) | Herbal composition for treatment of back pain |